CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer.
Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
卵巢癌被认为是全球范围内最具侵袭性和最致命的妇科恶性肿瘤之一。遗憾的是，目前被视为金标准的治疗方法与频繁复发相关。卵巢癌的生存率与肿瘤内高数量的浸润性淋巴细胞（TILs）相关。因此，免疫调节被认为在癌症治疗中具有重要作用，而免疫检查点抑制剂可能有助于恢复T细胞介导的抗肿瘤免疫。然而，迄今为止文献中呈现的数据尚不足以在卵巢癌患者中识别和选择真正对免疫治疗有反应的患者。尽管有一些研究显示了有利结果，但在这方面仍需要更多前瞻性试验。本综述聚焦于PD-1/L1阻断在卵巢癌中的当前和未来前景，并分析了所使用的最重要的免疫检查点抑制剂，以期实现最佳临床结局。未来需要更多研究和试验，以最大化免疫检查点阻断疗法在卵巢癌以及一般而言在所有癌症中的疗效。
Ovarian cancer is considered one of the most aggressive and deadliest gynecological malignancies worldwide. Unfortunately, the therapeutic methods that are considered the gold standard at this moment are associated with frequent recurrences. Survival in ovarian cancer is associated with the presence of a high number of intra tumor infiltrating lymphocytes (TILs).
Therefore, immunomodulation is considered to have an important role in cancer treatment, and immune checkpoint inhibitors may be useful for restoring T cell-mediated antitumor immunity.
However, the data presented in the literature until now are not sufficient to allow for the identification and selection of patients who really respond to immunotherapy among those with ovarian cancer. Although there are some studies with favorable results, more prospective trials are needed in this sense.
This review focuses on the current and future perspectives of PD-1/L1 blockade in ovarian cancer and analyzes the most important immune checkpoint inhibitors used, with the aim of achieving optimal clinical outcomes. Future studies and trials are needed to maximize the efficacy of immune checkpoint blockade therapy in ovarian cancer, as well as in all cancers, in general.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
